A phase 1 clinical trial (NCT06343805) is evaluating the safety and efficacy of AJ1-11095 in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.